Delivery Order SPE2DB22D2007-SPE2DB25FJ5AD
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $32,961.43 by the Defense Logistics Agency's Medical Supply Chain on August 18, 2025, for the supply of Enbrel 50 mg/ml SureClick auto-injectors. The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. The delivery order is scheduled for completion by August 19, 2025, and will be...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $13,880.31 by the Defense Logistics Agency for the supply of Enbrel 50 mg/ml SureClick auto-injectors. The order, issued on September 4, 2025, with an ultimate completion date of September 5, 2025, carries a firm fixed price and represents a non-competitive, non-set-aside award. The place of performance is listed as AmerisourceBergen's corporate...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order for Enbrel 50 mg/ml SureClick auto-injector pharmaceutical product valued at $75,487.57 by the Defense Logistics Agency's Medical Supply Chain on September 23, 2025. This firm fixed price delivery order, with an ultimate completion date of September 24, 2025, represents a non-competitive, non-set-aside award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 23, 2025, for Enbrel 50 mg/ml SureClick auto-injectors with a ceiling value of $4,626.77. This firm fixed-price, non-set-aside contract is funded through the Defense Logistics Agency's Medical Supply Chain and is set to complete by September 24, 2025. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor supporting federal medical...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $16,091.40 by the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract is a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and represents performance at the vendor's location in Conshohocken, Pennsylvania. This award is a non-set-aside competitive award, reflecting AmerisourceBergen's capability to meet federal procurement...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at $21,811.13 for ENBREL 50 MG/ML SureClick auto-injector medication. The contract, awarded on June 24, 2025, with an ultimate completion date of June 25, 2025, was competitively awarded with no set-aside designation. The delivery order is being funded by the Defense Logistics Agency's Medical Supply Chain division and will be performed...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order contract on September 9, 2025, for ENBREL 50 mg/mL SureClick auto-injectors with a firm fixed price ceiling value of $16,683.65. The contract is unclassified with no set-aside designation and carries an ultimate completion date of September 10, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) valued at $9,253.56 for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This firm fixed price, competitively awarded contract carries an ultimate completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under a larger indefinite delivery contract vehicle and reflects the DLA's...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $74,662.13 for the supply of Enbrel 50 mg/ml SureClick auto-injectors. The contract, awarded on September 11, 2025, with an ultimate completion date of September 12, 2025, is structured as a firm fixed price delivery order with no set-aside designation. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office....
- AmerisourceBergen Drug Corp was awarded a $67,062.44 firm fixed-price delivery order by the Defense Logistics Agency's Medical Supply Chain on September 26, 2025, for the supply of Enbrel 50 mg/ml SureClick auto-injector pens. The contract, which is a child award under a larger indefinite delivery contract vehicle, carries an ultimate completion date of September 29, 2025, and was competitively awarded with no set-aside designation. Performance will be executed from the company's corporate...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5ADDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $46,557.92 by the Defense Logistics Agency (DLA) on September 16, 2025, for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This competitive award, which carries no set-aside designation, is structured as a firm fixed price delivery order with an ultimate completion date of September 17, 2025. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing $999.99 billion Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and running through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. The Enbrel delivery represents a continuation of the company's critical role in supplying specialty medications and biologic therapies to the Defense Health Agency and other federal healthcare customers, demonstrating AmerisourceBergen's ongoing capacity to meet federal medical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.6k | 9/16/25 |